Isotechnika, Paladin, ILJIN deal

Paladin granted Isotechnika rights to develop and commercialize voclosporin for psoriasis and transplant indications in Latin and Central America. Paladin received $1 million up front and is eligible for royalties. Paladin said Isotechnika would sublicense rights in the territories to ILJIN's ILJIN Life Science Co. Ltd. subsidiary. Paladin also sold 12.5 million shares of Isotechnika stock to ILJIN for $3.3 million. ...